Form 4: Evoke Pharma CEO Matthew D'Onofrio Acquires 70,000 Stock Options

Evoke Pharma's CEO, Matthew J. D'Onofrio, was granted 70,000 stock options on January 28, 2025, according to a Form 4 filing with the SEC.

Summary

• Matthew J. D'Onofrio, CEO of Evoke Pharma Inc., acquired 70,000 stock options on January 28, 2025.
• The options have an exercise price of $4.45.
• The options vest over three years, with one-third vesting on the first anniversary and the remainder vesting monthly thereafter, contingent upon continuous service to the company.
• The options expire on January 27, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• The vesting schedule of one-third after one year and the remainder monthly thereafter is a fairly standard vesting arrangement.
• Comparing the size of the grant to similar companies and executive roles would provide further context on its relative value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to increase shareholder value.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Evoke Pharma, CEO, Matthew D'Onofrio, Form 4, beneficial ownership, equity, vesting